Trials / Completed
CompletedNCT04718922
Chlorhexidine Mouthrinse Before EBUS-TBNA
Effect of Chlorhexidine Mouthrinse on Prevention of Microbial Contamination During EBUS-TBNA: a Randomized Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
Detailed description
EBUS-TBNA using the convex probe is a standard of care for the assessment of mediastinal and hilar lymphadenopathy. Although EBUS-TBNA is a minimally invasive procedure, rare but serious infectious complications such as pneumonia, lung abscess, empyema, mediastinal adenitis/abscess, mediastinitis, pericarditis, and sepsis were reported. EBUS-scope might be contaminated with oropharyngeal commensal bacteria while passing the oropharyngeal airway during EBUS-TBNA. Contamination of punctured lymph nodes by oropharyngeal commensal bacteria can cause severe infections. Chlorhexidine gluconate is an antimicrobial agent that has a broad antibacterial activity including both gram-positive and negative bacteria. Chlorhexidine has been widely used for surgical scrub, skin disinfection, and mouthrinse. We, therefore, designed a phase 4, single-center, randomized, controlled clinical trial to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during EBUS-TBNA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chlorhexidine Gluconate 0.12 % Mouthwash | Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA |
Timeline
- Start date
- 2021-01-20
- Primary completion
- 2021-06-11
- Completion
- 2021-12-11
- First posted
- 2021-01-22
- Last updated
- 2022-02-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04718922. Inclusion in this directory is not an endorsement.